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TRANSLATIONAL IMMUNOLOGY IN KIDNEY DISEASE, ISN NEXUS SYMPOSIUM 2016cyclosporine was successful in 75% of patients in treating frequent
relapses. Mean time to achieve remission was 3.2 months. Overall
Tacrolimus was successful in 77% of patients in treating frequent
relapses. Mean time to achieve remission was 2.1 months. Out of 15
patients with steroid resistant nephrotic syndrome, 3 patients
treated with cyclosporine, 1 achieved partial remission and still
continued on CSA where as 2 patients did not respond. Time to
achieve remission was 5 months. 2 patients resistant to cyclosporine
and 12 steroid resistant patients were treated with tacrolimus (total
14 patients). 11 of 14 (79%) patients achieved complete remission
and 2(14%) achieved partial remission. Mean time to achieve
remission was 2.5 months. In SRNS patients, tacrolimus was more
effective than cyclosporine and was also effective in 1 pt resistant
to CSA.
Conclusions: In frequent relapsing nephrotic syndrome patients,
both cyclosporine and tacrolimus has comparable efﬁcacy and no
signiﬁcant difference. Overall success rate (CR, PR and infrequent
relapses) was 75% and 77% respectively. In steroid resistant
nephrotic syndrome patients, tacrolimus was more effective than
cyclosporine and also effective in CSA resistant patients. Combined
remission rate (CR & PR) of 93% with tacrolimus as compare to only
33% with cyclosporine was achieved in SRNS. Late steroid resis-
tance is associated with better response to CNI therapy as compared
to primary CNI resistance.
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Introduction: Current guidelines suggest treatment with cortico-
steroids (CS) in IgA nephropathy (IgAN) with persistent proteinuria
>1 g/day despite 3–6 months of supportive care and eGFR
>50 ml/min/1.73m2. Whether the beneﬁts of this treatment extend
to patients with an eGFR<50 ml/min/1.73m2 is unclear. We
retrospectively studied the effect of steroids on disease progression
and proteinuria in IgA N patients with eGFR < 50ml/min/1.73m2
compared to those with >50ml/min/1.73m2.
Methods: A cohort of biopsy proven primary IgA N diagnosed
between March 2010 and February 2015 who received oral corti-
costeroids and followed-up for a minimum of six months were
included. They were categorized into two groups as per eGFR.
(Group 1 – eGFR>50 ml/min/1.73m2, Group 2 – eGFR < 50ml/min/
1.73m2). Baseline characteristics were compared between the
groups. The eGFR and urine protein creatinine ratio (UPCR) were
followed up at entry time, 6 months, 12 months and at the end of
follow-up. Outcomes studied were change in eGFR, proteinuria and
progression to end stage renal disease (ESRD). Statistical analysis
was done using SPSS version 16.
Results: Out of 44 patients, 23(52%) had eGFR< 50 ml/min/1.73m2
(Group1) and 21(48%) had eGFR >50ml/min/1.73m2 (Group 2). The
baseline clinical, histopathological, and treatment characteristics of
both the groups are shown in table 1. At the end of follow-up,Kidney International Reports (2016) 1, S1–S22similar reduction of proteinuria (UPCR) (p-0.62) was seen in both
the groups. But there was signiﬁcant difference in change in me-
dian eGFR/month (p-0.004) (Table 2). Patients in Group 2 had a
median fall in eGFR of -0.46 ml/min/1.73m2 / month, whereas
Group 1 had an increase in median eGFR by +0.38ml/min/1.73m2/
month (Table 2). One in each group has reached CKD stage
5(p-0.73). Limitations in our study were retrospective in nature,
small cohort and short duration of follow-up.
Table 2. Outcomes at the end of follow-up between groups
Group 1(N[23) (%) Group 2-(N-21)(%)Characteristic
(eGFR < 50
ml/min/1.73m2)
(eGFR > 50
ml/min/1.73m2)
‘p’
valueInitial eGFR# 25.13(19.33,39.51) 82.7(76,115.85)eGFR at end of follow-
up#20.94(9.36,37.12) 94.43(77.48,129.91)Change in eGFR/
month#-0.46(-0.1,-1.08) +0.38(+1.06,0.00) 0.004Initial UPCR# 2.6(1.8,3.3) 2(1.7,3.1)UPCR at the end of
follow-up#1.0(0.6,2.0) 1.0(0.6,2.0)Change in UPCR# 1.4(0.3,2.0) 1.5(0.55,2.75) 0.61Patients reaching ESRD 1(4.3) 1(4.7) 0.73#- Median with interquartile range, *- Mean with standard deviation, estimated
glomerular ﬁltration rate (eGFR), Urine protein-to- creatinine ratio(UPCR)
Conclusions: Addition of corticosteroids to conservative treatment
in IgA N patients with initial eGFR<50 ml/min/1.73m2 seems to
reduce proteinuria but not beneﬁcial in preventing progression of
disease as compared to patients with higher eGFR (>50ml/ min/
1.73m2). However we need large prospective randomized control
trials with long term follow-up to conﬁrm role of steroids in this
subset of IgA N.
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Introduction: Current guidelines do not mention tacrolimus (TAC)
as a treatment option and no consensus has been reported on the
role of tacrolimus in active LN. Recent clinical trials have reported
positive effects of tacrolimus-based regimens for treatment of lupus
nephritis (LN). In order to translate these trials into clinical prac-
tice, we systematically reviewed all clinical studies published thus
far that investigated TAC regimens in LN patients and performed a
meta-analysis.
Methods:We identiﬁed from various databases every clinical study
investigating TAC regimens in LN. Studies were summarized on the
basis of treatment target (induction or maintenance), concomitant
immunosuppression and quality of the data. A meta-analysis was
performed for the efﬁcacy of TAC regimens as induction treatment.
Results: 239 studies were identiﬁed from which 24 were clinical
studies performed in LN patients: 6 case series, 9 cohort studies, 3
case-control studies (CCS) and 6 randomized controlled trials
(RCTs). Further analysis of the 9 controlled trials showed that 7
studies investigated tacrolimus in combination with steroids and 2
tacrolimus with mycophenolate plus steroids. 4 RCTs investigated
TAC regimens as induction treatment and 2 RCTs as maintenance
treatment. Strikingly, there was no consensus in any of the studies
regarding tacrolimus dosing and target trough levels. Importantly,
all the studies were performed in LN patients of Asian ethnicity. A
meta-analysis of TAC regimens for induction treatment showed a
signiﬁcantly higher complete response (RR 1.18, 95% CI 1.04-1.34,
p ¼ 0.01) and a signiﬁcantly lower no response rate (RR 0.71, 95%
CI 0.56-0.90, p<0.01). With respect to safety, no clear differences
between TAC regimens and conventional treatment were observed.
Conclusions: Current studies on TAC regimens for LN are limited,
heterogeneous and predominant uncontrolled studies in patients of
Asian ethnicity. A signiﬁcant clinical efﬁcacy of TAC regimens as
induction treatment was found. However, this cannot be extrapo-
lated beyond Asian LN patient groups. Clearly, these results
mandate further conﬁrmation in multi-ethnic, randomized trials.
P29
LEARNING ABOUT HUMAN KIDNEY
IMMUNOLOGY FROM THERAPEUTIC
MONOCLONAL ANTIBODY-INDUCED
KIDNEY INJURY: EFFECT OF PD1
BLOCKADE
Muczynski, K1, Torres, MJ1, Kwiatkowski, J2,
Anderson, SK1
1University of Washington, Medicine-Nephrology, Seattle, USA; 2Jagiello-
nian University Medical College, School of Medicine, Krakow, Poland
Introduction: Human renal microvascular endothelial cells (RMEC)
normally express high levels of HLA class II, even when no
inﬂammation is present by histology. Previous work in the lab with
isolated (cultured) RMEC showed that the cells present peptide in a
DR restricted manner to activate antigen-speciﬁc T cells. T cell
proliferation and cytokine secretion were decreased by CD40 and
CD58 antibodies and increased with CD274 (PD-L1) antibodies. We
hypothesized that RMEC express T cell inhibitory molecules in
vivo to prevent or limit T cell activation to HLA class II presented
peptides.
Nivolumab, a programed death 1 (PD1) inhibitor, is a new
immunotherapy option for a growing number of cancer types,
including lung cancer, advanced renal cell carcinoma, and meta-
static melanoma. It selectively binds PD1 to prevent interactionS14with its ligands PD-L1 (CD274, B7H1) and PD-L2 (CD273, B7H2).
PD-1 is expressed on activated T and B lymphocytes and myeloid
cells. Binding to its ligands transmits an inhibitory signal which
reduces the proliferation of these cells. Expression of PD1 ligands
on tumor cells enables them to suppress lymphocyte responses to
tumor antigens. Monoclonal antibodies targeting PD1 removes this
suppression, thereby enhancing T-cell responses to promote anti-
tumor activity.
Methods: Flow cytometry was used to identify RMEC and assess
their expression of PD1 ligands and T cell co-stimulatory proteins.
Medical records and pathology slides were reviewed for patients
who developed acute kidney injury while being treated with
nivolumab.
Results: Flow cytometry studies identiﬁed high levels of PD-L1 on
RMEC from normal human kidneys.
Four patients were identiﬁed who developed acute kidney
injury while receiving PD1 blocking antibody therapy for their
cancers. Three underwent renal biopsy which showed interstitial
nephritis with intense inﬂammation around capillaries. Other cau-
ses of interstitial nephritis were not identiﬁed from clinical history.
Conclusions: Our interpretation of RMEC’s ability to activate T
cells in a class II-peptide dependent manner, their high levels of
inhibitory ligand PD-L1 (CD274) and now the development of
interstitial inﬂammation in some patients receiving anti-PD1
monoclonal therapy is that RMEC are poised to present peptide
from circulating antigen as an immune surveillance system, with
the PD1 pathway functioning to restrain T cell activation. Other
human organs also express high levels of HLA class II on micro-
vascular endothelial cells. Hence our hypothesis of a kidney
capillary endothelium forming an immune surveillance system may
also pertain to other organs.
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Introduction: Chronic kidney disease (CKD) is a major risk factor for
cardiovascular disease (CVD), partly due to endothelial dysfunc-
tion, and chronic inﬂammation. Disturbed function of the immune
system in CKD patients is witnessed through the high levels of
cytokines in the plasma, and epigenetic modiﬁcations such as micro
RNAs (miRs) expression contribute to the disease process. Vitamin
D supplementation or treatment, protect endothelial function and
may improve outcome in these patients. In the SOLID-trial, we
showed that treatment with a vitamin D receptor activator, (VDRA;
paricalcitol) is followed by a maintained endothelial function and
capillary blood ﬂow. Here, we report the effect of paricalcitol on
pro-inﬂammatory cytokines and miRs in plasma from patients in
the SOLID-trial.
Methods: 36 patients with eGFR of 15-59 mL/min/1.73 m2, calcium
< 2.6 mmol/L, and PTH level of 35-500 pg/mL were randomized
to 12 weeks treatment with placebo, 1 mg, or 2 mg paricalcitol.Kidney International Reports (2016) 1, S1–S22
